Board Committees

Mr. Stuart Duty is an experienced financial executive with over 30 years in finance and investment banking building leading healthcare teams on multiple platforms with a history of substantial growth in both revenue and personnel. Mr. Duty has focused primarily on biotechnology and specialty pharmaceuticals clients for much of his career, advising senior executives and boards on a range of financing activities and strategic transactions. His advisory activities spanned a global client base including significant in-country and cross-border transactions in the US, Japan, China, Canada and many European countries. Mr. Duty was a Senior Managing Director at Guggenheim Securities, LLC from 2012 to 2023. Previously, he held senior roles at Piper Jaffray and Montgomery Securities. Mr. Duty also held operating roles at Oracle Partners as Chief Operating Officer and at Curative Technologies as Director, Business Development. He began his career at Kidder Peabody. Mr. Duty holds a B.A. in Biochemistry from Occidental College and an M.B.A from Harvard Business School.

Dr. Martell is a high impact, results-oriented scientific biotech executive with breadth and depth in clinical development, medical affairs, and business development across a range of therapeutic areas from first in human to approval and commercialization. Dr. Martell brings extensive scientific acumen to her leadership roles and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla®, Elelyso®, Intermezzo®, the trastuzumab biosimilars Ogiviri®, as well as secondary indications for Pradaxa® and Sutent®. Dr. Martell is currently President and CEO of Artizan Biosciences, Inc. and an independent Director for Aligos Therapeutics. She has held leadership and C-suite executive roles at companies including Artizan Biosciences where she led a precision medicine drug development platform company focusing on inflammatory diseases, Kura Oncology where she led the Menin Inhibitor Program and at Juniper Pharmaceuticals where she led the development program for a Bob Langer combined drug device technology that was out licensed for $131M. She started her pharma career at Pfizer where she had roles of increasing responsibility that included Clinical Team Leader for Sutent® GU solid tumors in the Oncology Business Unit and ultimately Biosimilars Medical Head. She began her clinical investigation career at Yale with a Career Development Award where she led a therapeutic cocaine vaccine trial and as Robert Wood Johnson Clinical Scholar. She was a practicing physician at Yale for 20 years and remains active as an Entrepreneur in Residence at Yale Ventures. Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. She is board certified in both Internal and Addiction Medicine.

Mr. Tom Sellig brings more than 30 years of global experience in the life sciences and pharmaceutical services industries. He is currently CEO of Adare Pharma Solutions, a global technology-driven Contract Development and Manufacturing Organization specializing in oral solid dosage forms. From 2019 to 2021 Tom served as Chief Executive Officer of LabConnect, a clinical trial laboratory services organization. Prior to LabConnect, Tom was Chief Commercial Officer at ConnectiveRx, where he was responsible for all commercial and customer-facing activity at the patient support and patient access company. Earlier, Tom was Senior Vice President of Global Sales at Patheon, where he played an integral role in the company’s sale to and integration with Thermo Fisher. Previously, he served as the Global Vice President of Sales and Client Services at Covance. Early in his career, Tom had a variety of sales and marketing leadership roles at Procter & Gamble, American Home Products, and Ascent Pediatrics. Tom received his bachelor’s degree in Economics from Vanderbilt University and an MBA from New York University.

Mr. Tom Sellig brings more than 30 years of global experience in the life sciences and pharmaceutical services industries. He is currently CEO of Adare Pharma Solutions, a global technology-driven Contract Development and Manufacturing Organization specializing in oral solid dosage forms. From 2019 to 2021 Tom served as Chief Executive Officer of LabConnect, a clinical trial laboratory services organization. Prior to LabConnect, Tom was Chief Commercial Officer at ConnectiveRx, where he was responsible for all commercial and customer-facing activity at the patient support and patient access company. Earlier, Tom was Senior Vice President of Global Sales at Patheon, where he played an integral role in the company’s sale to and integration with Thermo Fisher. Previously, he served as the Global Vice President of Sales and Client Services at Covance. Early in his career, Tom had a variety of sales and marketing leadership roles at Procter & Gamble, American Home Products, and Ascent Pediatrics. Tom received his bachelor’s degree in Economics from Vanderbilt University and an MBA from New York University.

Dr. Martell is a high impact, results-oriented scientific biotech executive with breadth and depth in clinical development, medical affairs, and business development across a range of therapeutic areas from first in human to approval and commercialization. Dr. Martell brings extensive scientific acumen to her leadership roles and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla®, Elelyso®, Intermezzo®, the trastuzumab biosimilars Ogiviri®, as well as secondary indications for Pradaxa® and Sutent®. Dr. Martell is currently President and CEO of Artizan Biosciences, Inc. and an independent Director for Aligos Therapeutics. She has held leadership and C-suite executive roles at companies including Artizan Biosciences where she led a precision medicine drug development platform company focusing on inflammatory diseases, Kura Oncology where she led the Menin Inhibitor Program and at Juniper Pharmaceuticals where she led the development program for a Bob Langer combined drug device technology that was out licensed for $131M. She started her pharma career at Pfizer where she had roles of increasing responsibility that included Clinical Team Leader for Sutent® GU solid tumors in the Oncology Business Unit and ultimately Biosimilars Medical Head. She began her clinical investigation career at Yale with a Career Development Award where she led a therapeutic cocaine vaccine trial and as Robert Wood Johnson Clinical Scholar. She was a practicing physician at Yale for 20 years and remains active as an Entrepreneur in Residence at Yale Ventures. Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. She is board certified in both Internal and Addiction Medicine.

Dr. Martell is a high impact, results-oriented scientific biotech executive with breadth and depth in clinical development, medical affairs, and business development across a range of therapeutic areas from first in human to approval and commercialization. Dr. Martell brings extensive scientific acumen to her leadership roles and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla®, Elelyso®, Intermezzo®, the trastuzumab biosimilars Ogiviri®, as well as secondary indications for Pradaxa® and Sutent®. Dr. Martell is currently President and CEO of Artizan Biosciences, Inc. and an independent Director for Aligos Therapeutics. She has held leadership and C-suite executive roles at companies including Artizan Biosciences where she led a precision medicine drug development platform company focusing on inflammatory diseases, Kura Oncology where she led the Menin Inhibitor Program and at Juniper Pharmaceuticals where she led the development program for a Bob Langer combined drug device technology that was out licensed for $131M. She started her pharma career at Pfizer where she had roles of increasing responsibility that included Clinical Team Leader for Sutent® GU solid tumors in the Oncology Business Unit and ultimately Biosimilars Medical Head. She began her clinical investigation career at Yale with a Career Development Award where she led a therapeutic cocaine vaccine trial and as Robert Wood Johnson Clinical Scholar. She was a practicing physician at Yale for 20 years and remains active as an Entrepreneur in Residence at Yale Ventures. Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. She is board certified in both Internal and Addiction Medicine.

Mr. Stuart Duty is an experienced financial executive with over 30 years in finance and investment banking building leading healthcare teams on multiple platforms with a history of substantial growth in both revenue and personnel. Mr. Duty has focused primarily on biotechnology and specialty pharmaceuticals clients for much of his career, advising senior executives and boards on a range of financing activities and strategic transactions. His advisory activities spanned a global client base including significant in-country and cross-border transactions in the US, Japan, China, Canada and many European countries. Mr. Duty was a Senior Managing Director at Guggenheim Securities, LLC from 2012 to 2023. Previously, he held senior roles at Piper Jaffray and Montgomery Securities. Mr. Duty also held operating roles at Oracle Partners as Chief Operating Officer and at Curative Technologies as Director, Business Development. He began his career at Kidder Peabody. Mr. Duty holds a B.A. in Biochemistry from Occidental College and an M.B.A from Harvard Business School.